Bristol Pharmaceutical has announced that it has been granted priority review status for entecavir [Baraclude],

Inpharma Weekly ◽

10.2165/00128413-200515140-00049 ◽

2005 ◽

Vol &NA; (1514) ◽

pp. 18

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Download Full-text

Novartis has received Priority Review status from Health Canada for deferasirox [Exjade]

Inpharma Weekly ◽

10.2165/00128413-200514970-00055 ◽

2005 ◽

Vol &NA; (1497) ◽

pp. 22

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Review Status ◽

Download Full-text

131I-Tositumomab ['Bexxar'; Corixa Corporation, GlaxoSmithKline] has been granted priority review status in Canada.

Inpharma Weekly ◽

10.2165/00128413-200314040-00054 ◽

2003 ◽

Vol &NA; (1404) ◽

pp. 22

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Review Status ◽

131I Tositumomab

Download Full-text

Schering-Plough's temozolomide [Temodal] capsule has been granted priority review status in Japan

Inpharma Weekly ◽

10.2165/00128413-200515130-00052 ◽

2005 ◽

Vol &NA; (1513) ◽

pp. 18

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Download Full-text

Letrozole [Femara; Novartis] has been granted priority review status by the US FDA

Inpharma Weekly ◽

10.2165/00128413-200515030-00055 ◽

2005 ◽

Vol &NA; (1503) ◽

pp. 22

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Review Status ◽

The Us ◽

Download Full-text

GlaxoSmithKline has been granted priority review status in Japan for adefovir dipivoxil [Hepsera; licensed from Gilead Sciences],

Inpharma Weekly ◽

10.2165/00128413-200414370-00057 ◽

2004 ◽

Vol &NA; (1437) ◽

pp. 21

Author(s):

&NA;

Keyword(s):

Adefovir Dipivoxil ◽

Priority Review ◽

Download Full-text

ISTA Pharmaceuticals' NDA* for ovine hyaluronidase ['Vitrase'] has been granted priority review status

Inpharma Weekly ◽

10.2165/00128413-200314020-00042 ◽

2003 ◽

Vol &NA; (1402) ◽

pp. 18

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Download Full-text

Schering-Plough's peginterferon (PEG IFN)-??-2b plus ribavirin [Peg-Intron plus Rebetol] has been granted priority review status in Japan for a new indication,

Inpharma Weekly ◽

10.2165/00128413-200514950-00060 ◽

2005 ◽

Vol &NA; (1495) ◽

pp. 23

Author(s):

&NA;

Keyword(s):

Priority Review ◽

Download Full-text

FDA Priority Review Status to Drugs for Metastatic Breast Cancer and NSCLC

Oncology Times ◽

10.1097/01.cot.0000479767.94710.d2 ◽

2016 ◽

Vol 38 (1) ◽

pp. 12

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Priority Review ◽

Download Full-text

FDA Priority Review Status for Defibrotide and Halaven

Oncology Times ◽

10.1097/01.cot.0000473104.86820.b7 ◽

2015 ◽

Vol 37 (20) ◽

pp. 17

Keyword(s):

Priority Review ◽

Download Full-text

Health Canada's use of priority review status for drugs for unmet needs

Regulatory Toxicology and Pharmacology ◽

10.1016/j.yrtph.2015.08.002 ◽

2015 ◽

Vol 73 (1) ◽

pp. 391-395 ◽

Author(s):

Nigel S.B. Rawson

Keyword(s):

Unmet Needs ◽

Priority Review ◽

Download Full-text